Cytokine MRNA Expression During an in Vitro Response of Human B Lymphocytes: Kinetics of B Cell Tumor Necrosis Factor Alpha, Interleukin (IL)6, IL-10, and Transforming Growth Factor Beta 1 MRNAs
Overview
General Medicine
Authors
Affiliations
Expression of mRNA for eight cytokines was analyzed in an in vitro response-proliferation and Ig-secretion--of normal human B lymphocytes. This was made possible by the use of murine thymoma cells as helper cells in conjunction with human T cell supernatant, and the design of human DNA sequence-specific primers for RT-polymerase chain reaction. mRNAs for interleukin (IL)2 and IL-4, but also for IL-1 alpha and IL-1 beta remained undetectable during the whole culture period in highly purified B cells prepared by a three-step purification protocol. However, tumor necrosis factor alpha and IL-6 mRNAs peaked during days 1-3 after culture start and became undetectable after 5-6 d, shortly before bulk B cell proliferation started to decline. In contrast, transforming growth factor beta 1 mRNA, after a progressive increase during the first few days, and IL-10 mRNA, after a peak on days 1-3, remained detectable in immunoglobulin (Ig)-secreting cultures throughout the observation period of 22 d. Clonal analysis on 8-d cultures that had been seeded with single B cells by autocloning with the cell sorter, revealed that 85% of 77 B cell clones studied, expressed TGF-beta 1 mRNA, and only 19% IL-10 mRNA. These findings show a differentiation stage-related cytokine program during a B cell response, whereby (a) B cells can become activated without IL-1 alpha or IL-1 beta expression; (b) mRNA for positive (IL-10) and negative (TGF-beta 1) autoregulatory factors coexists in cell populations during the later phase of the response, although not necessarily in all B cell clones; and (c) normal Ig-secreting cells cease IL-6 expression in contrast to their malignant counterparts, myeloma cells.
Cytokine production by human B cells: role in health and autoimmune disease.
de Gruijter N, Jebson B, Rosser E Clin Exp Immunol. 2022; 210(3):253-262.
PMID: 36179248 PMC: 9985175. DOI: 10.1093/cei/uxac090.
Berglund L, Avery D, Ma C, Moens L, Deenick E, Bustamante J Blood. 2013; 122(24):3940-50.
PMID: 24159173 PMC: 3854113. DOI: 10.1182/blood-2013-06-506865.
Benkoe T, Baumann S, Weninger M, Pones M, Reck C, Rebhandl W PLoS One. 2013; 8(3):e58720.
PMID: 23472217 PMC: 3589358. DOI: 10.1371/journal.pone.0058720.
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.
Frecha C, Levy C, Cosset F, Verhoeyen E Mol Ther. 2010; 18(10):1748-57.
PMID: 20736930 PMC: 2951569. DOI: 10.1038/mt.2010.178.
Kurt A, Aygun A, Godekmerdan A, Kurt A, Dogan Y, Yilmaz E Mediators Inflamm. 2008; 2007:31397.
PMID: 18274637 PMC: 2220039. DOI: 10.1155/2007/31397.